{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:23:24Z","timestamp":1787768604549,"version":"build-2784847793"},"reference-count":7,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013]]},"DOI":"10.4103\/0022-3859.118059","type":"journal-article","created":{"date-parts":[[2013,9,12]],"date-time":"2013-09-12T04:17:55Z","timestamp":1378959475000},"page":"244-245","source":"Crossref","is-referenced-by-count":15,"title":["Imatinib induced pyoderma gangrenosum"],"prefix":"10.4103","volume":"59","author":[{"given":"DJ","family":"Pinato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-22-20240205","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1200\/JCO.2007.13.4403","article-title":"Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT","volume":"26","author":"Blanke","year":"2008","journal-title":"J Clin Oncol"},{"key":"R2-22-20240205","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1111\/j.1365-4632.2006.02749.x","article-title":"Adverse reactions to gefitinib (Iressa): Revealing sycosis-and pyoderma gangrenosum-like lesions","volume":"45","author":"Sagara","year":"2006","journal-title":"Int J Dermatol"},{"key":"R3-22-20240205","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1365-2133.2008.08599.x","article-title":"Pyoderma gangrenosum: Another cutaneous side-effect of sunitinib?","volume":"159","author":"ten Freyhaus","year":"2008","journal-title":"Br J Dermatol"},{"key":"R4-22-20240205","first-page":"228","article-title":"Imatinib mesylate and dermatology part 2: A review of the cutaneous side effects of imatinib mesylate","volume":"5","author":"Scheinfeld","year":"2006","journal-title":"J Drugs Dermatol"},{"key":"R5-22-20240205","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/S1470-2045(10)70222-9","article-title":"Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: An open-label multicentre randomised phase 3 trial","volume":"11","author":"Le Cesne","year":"2010","journal-title":"Lancet Oncol"},{"key":"R6-22-20240205","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1080\/13577140500349717","article-title":"Management of skin toxicity related to the use of imatinib mesylate (STI571, Glivectrade mark) for advanced stage gastrointestinal stromal tumours","volume":"9","author":"Scott","year":"2005","journal-title":"Sarcoma"},{"key":"R7-22-20240205","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-4632.2004.01975.x","article-title":"Erythroderma\/exfoliative dermatitis: A synopsis","volume":"43","author":"Sehgal","year":"2004","journal-title":"Int J Dermatol"}],"container-title":["Journal of Postgraduate Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00005257-201359030-00022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:17:04Z","timestamp":1787768224000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00005257-201359030-00022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":7,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.4103\/0022-3859.118059","relation":{},"ISSN":["0022-3859"],"issn-type":[{"value":"0022-3859","type":"print"}],"subject":[],"published":{"date-parts":[[2013]]}}}